The announcement of IFXIIIS 2015 in Dusseldorf

The announcement of IFXIIIS 2015 in Dusseldorf


Dear Friends:

We are very glad that we can announce the annual International Factor XIII/13 Symposium
in Dusseldorf, Germany, on February 24 Wednesday, 2015, through the courtesy of the
president of the 59th GTH meeting (
As usual, we will stick to the “traditional” conditions offered by the president. That
includes waiver of registration for the participants who only join IFXIIIS.

Participants visiting the IFXIIIS 2015 only are permitted free access. Any participant who
wants to stay longer for another GTH session needs to pay the congress registration fee as follows:
If a participant wants to attend our workshop exclusively (free participation) he has to register online
with the registration code FactorXIII.
( ).
He has also the possibility to register on site at the congress counter. This way of registration will
actually only allow him/her to participate in this specific workshop. Everybody who wants to attend
the Get Together, the exhibition or the congress has to register regularly for the congress.

Looking forward to meeting you in Vienna, soon.

Chairmen of IFXIIIS
Prof. Aki Ichinose,
Prof. Hans Kohler

The program of the the IFXIIIS 2015 in Dusseldorf, Germany


International Factor XIII Symposium in Dusseldorf
12:30 to 16:15 on Tuesday 24 February, 2015
in Room 3 at the CCD Congress Center Düsseldorf, Germany.
Chairs: Profs. Akitada Ichinose (Yamagata, Japan) and Hans Kohler (Bern, Switzerland)

“Continuing Progress in Factor XIII Research”

<Basic Science>
1) Active factor XIII-A is exposed on the stimulated platelet membrane (20 min)
Mutch NJ
(Department of Medicine & Dentistry, University of Aberdeen, Aberdeen, UK)

2) Role of FXIII activation peptides for FXIII activity (15 min)
Johannes Dodt
(Blood Coagulation Products II, Paul-Ehrlich-Institut, Langen, Germany)

3) FXIII and Fibrinogen Interactions (15 min)
Helen Philippou
(Faculty of Medicine and Health, University of Leeds, Leeds, UK)

4) Tightening fibrin clots: the mechanical role of FXIII in fibrin clot maturation and stiffening (20 min)
Kurniawan NA and Koenderink G
(FOM Institute AMOLF, Amsterdam, The Netherlands)

5) Using mass spectrometry and proteomics in factor XIII research (20 min)
Nikolajsen CL, Scavenius C, Enghild JJ
(Department of Molecular Biology and Genetics, University of Aarhus, Aarhus, Denmark)

6) Functional Modification of Fibronectin by Factor XIII for Extracellular Matrix Engineering (15 min)
Schoen I, Früh SM, Spycher PR, Vogel V
(Laboratory of Applied Mechanobiology, Department of Health Sciences and Technology, ETH Zurich, Switzerland)

<Intermission (5 min) >

<Clinical Science>
7) Trial to measure coagulation factor XIII activity with a clotting time method (15 min)
Oda Y (1, 2), Ieko M (1)
(1) Department of Internal Medicine, Health Sciences University of Hokkaido, Japan, (2) Kyowa Medex Co.,Ltd., Japan

8) Discrepancies between plasma FXIII values and genetic status of patients with congenital FXIII deficiency: experience of Bonn Hemophilia Center (15 min)
Ivaskevicius V, Biswas A and Oldenburg J
(Insitute of Experimental Haematology and Transfusion Medicine, Bonn, Germany)

9) Pharmacokinetics of recombinant FXIII at steady-state in patients with congenital FXIII A-subunit deficiency (20 min)
Kerlin B, Brand B, Inbal A, Halimeh S, Nugent D, Lundblad M, Tehranchi R
(Nationwide Children’s Hospital and The Ohio State University College of Medicine, Columbus, OH, USA)

10) The current status of autoimmune hemorrhaphilia due to anti-FXIII/13 antibodies and its related diseases in Japan (15 min)
Ichinose A
(Yamagata University School of Medicine, Yamagata, Japan) on behalf of the Japanese collaborative research group on AHXIII/13

11) Management of autoimmune hemorrhaplilia XIII/13 (AH13) complicated by pulmonary thromboembolism (15 min)
Ogawa Y (1), Yanagisawa K (1), Ichinose A (2, 3)
(1) Gumma University School of Medicine, Maebashi, Japan; (2) Yamagata University School of Medicine, Yamagata, Japan; (3)the Japanese collaborative research group on AHXIII/13

12) Factor XIII levels after cardiopulmonary bypass in children with different types of congenital heart defects: correlation with other coagulation and clinical parameters (20 min)
Bockeria LA (1), Samsonova NN(1), Yurlov IA(1), Olsen EHN(2), Zaets SB (2)
(1) Bakoulev Center for Cardiovascular Surgery, Moscow, Russia; (2) Novo Nordisk Inc., Plainsboro, NJ, USA

13) Factor XIII B subunit polymorphisms and the risk of coronary artery disease; interaction with fibrinogen level and FXIII-A p.Val34Leu polymorphism (15 min)
Zoltán A. Mezei (1), Zsuzsanna Bereczky (1), Éva Katona (1), Réka Gindele (1), Emília Balogh (2), Szilvia Fiatal (3), László Balogh (2), István Czuriga (2), Róza Ádány (3), István Édes (2), László Muszbek (1,4)
(1)Division of Clinical Laboratory Science, Department of Laboratory Medicine, (2)Department of Cardiology, (3)Department of Preventive Medicine, (4)Vascular Biology, Thrombosis and Hemostasis Research Group of the Hungarian Academy of Sciences, University of Debrecen, Debrecen, Hungary

If you have any questions, please do not hesitate to contact us (mailing address: